Shield Therapeutics plc

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

G7997R103

SEDOL

BYV8129

CIK

N/A

shieldtherapeutics.com

LEI:

FIGI: BBG009YWHXG4

STX

Shield Therapeutics plc

GICS: - · Sector: Health Care · Sub-Sector: Health Care

PROFILER

NAME

Shield Therapeutics plc

ISIN

GB00BYV81293

TICKER

STX

MIC

AIMX

REUTERS

STX.L

BLOOMBERG

STX LN

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Mon, 11.11.2024

Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. Register for the event to secure your place and submit questions. A commercial-stage pharmaceutical company,...

Research & Analysis

Wed, 11.09.2024

Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating...

Research & Analysis

Thu, 23.05.2024

Hardman & Co Research on Shield Therapeutics (STX): Cash management is key Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness...

Research & Analysis

Wed, 15.11.2023

Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awa...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Shield Therapeutics plc

Shield Therapeutics (STX) Investor Forum

Focusing on successful execution

Cash management is key

Accelerating effectiveness of enlarged sales team

Newsletter